Wanbury Limited Awards for Tanuku and Patalganga Facilities

Wanbury Limited Regd. Office: BSEL Tech Park, B- Wing, 10th Floor, Sector-30A, Opp. Vashi Railway Station, Vashi, Navi Mumbai 400703 Maharashtra, INDIA Tel: +91-22-6794 2222 +91-22-7196 3222 CIN: L51900MH1988PLC048455 Email: info@wanbury.com Website: www.wanbury.com October 19, 2026 BSE Limited National Stock Exchange of India Ltd, PJ. Towers, Exchange Plaza, Dalal Street Bandra Kurla Complex, Mumbai – 400 001. Bandra (East), Mumbai -400 051. Script Code: 524212 Script Code: WANBURY Dear Sir/Madam, Sub.: Wanbury Limited – Awards for Tanuku and Patalganga Facilities Pursuant to Regulation 30 of SEBI LODR, we wish to inform you as under: Please find enclosed the press release highlighting the Company's progress in employee practices and safety performance in its API business This is for your information and records. Thanking you. Yours faithfully, For Wanbury Limited Jitendra J. Gandhi Company Secretary Encl.: a/a US Europe Brazil Korea India Mexico Canada China WHO GMP PRESS RELEASE Awards for Tanuku and Patalganga Facilities Wanbury’s Tanuku and Patalganga Facilities Win Awards for Employee Practices and Safety Performance Mumbai, October 19, 2026 — Wanbury Limited today announced that it has received the highest recognition from the National Safety Council for its outstanding safety performance, and that its Andhra Pradesh API manufacturing site has been named “Best Employer” by the State Government. Recognition for people and safety • Patalganga, Maharashtra (API manufacturing): received the “Certificate of Excellence” from the National Safety Council for safety performance for the third consecutive year. • Tanuku, Andhra Pradesh (API manufacturing): received the “Best Employer Award” from the State Government, recognising its employee practices and workplace culture. Wanbury is committed to upholding high environment, health and safety (EHS) standards while complying with Good Manufacturing Practice (GMP) norms and supply APIs to customers across global markets. Management comment “Our people and their safety are at the heart of everything we do,” said Mr. Mohan Rayana, Director of Wanbury Limited. “These awards for our Tanuku and Patalganga teams recognise their dedication to a safe, compliant and rewarding workplace. We will keep raising the bar on employee welfare and safety across all our sites.” US Europe Brazil Korea India Mexico Canada China WHO GMP About Wanbury Ltd: Established in 1988, listed on the National Stock Exchange of India Ltd (Code: WANBURY) and BSE Ltd (Code: 524212). The company has a strong presence in API global market and domestic branded Formulation with its API being exported to over 50 countries and has Pan-India Formulation presence. The company has USFDA & EUGMP approved facilities at Tanuku (Andhra Pradesh) and Patalganga (Maharashtra). The API product portfolio includes Antidiabetic, Antidepressant, Pain management, Antihistamine, Anti-inflammatory, Antidepressant and various other products in pipeline. The company's clients include some of the leading global generic players. In formulations, the company has a wide presence across major therapeutic categories like cough and cold solutions, gynecology, orthopedics, nutraceuticals, gastrointestinal, anti-inflammatory, & analgesics. For more details on Wanbury Ltd.: https://www.wanbury.com/ For any Investor Relations query, please contact: Jitendra J. Gandhi Smit Shah / Hanishi Shah Company Secretary, Adfactors PR Wanbury Limited Oasis Complex, Kamala Mills Compound, BSEL Techpark,B' Wing, 10th Floor, City Hall, Pandurang Budhkar Marg, Sector 30-A,Opp. Vashi Railway Station, Lower Parel West, Mumbai – 400021 Vashi, Navi Mumbai - 400703, Tel : +91 9870789596 / +91 9619059339 Maharashtra, India. Email : smit.shah@adfactorspr.com / Tel: +91-22-6794 2222 hanishi.shah@adfactorspr.com Email: jitendra.gandhi@wanbury.com Caution Concerning Forward- Looking Statements: This document may contain statements, which reflect management’s current views and estimates and could be construed as forward-looking statements. The future involves certain risks and uncertainties and could cause actual results to differ materially from the current views being expressed. Potential risks and uncertainties include factors such as general economic conditions, foreign exchange fluctuation, pricing pressures, competition and regulatory developments. US Europe Brazil Korea India Mexico Canada China WHO GMP